NE Lincoln의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 16개가 Lincoln 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중2상
- Nebraska Hematology-Oncology /ID# 272970, Lincoln
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
피험자 모집 중2/3상
- Nho - Revive Research Institute /ID# 277569, Lincoln
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
피험자 모집 중3상
- Cancer Partners of Nebraska, Lincoln
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
피험자 모집 중3상
- Nebraska Hematology-Oncology - Revive Research Institute LLC, Lincoln
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
피험자 모집 중3상
- NHO Revive Research Institute, LLC ( Site 3218), Lincoln
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
피험자 모집 중3상
- NHO Revive Research Institute LLC ( Site 0118), Lincoln
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
피험자 모집 중3상
- Research Site, Lincoln
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
피험자 모집 중3상
- NHO Revive Research Institute, LLC, Lincoln
- NHO Support Center, Lincoln
- Cancer Partners of Nebraska, Lincoln
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
피험자 모집 중3상
- Cancer Partners of Nebraska, Lincoln
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
피험자 모집 중2상
- Cancer Partners of Nebraska, Lincoln
Pan-tumor MRD Study
피험자 모집 중관찰 연구
- Cancer Partners of Nebraska, Lincoln
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
피험자 모집 중3상
- Research Site, Lincoln
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
피험자 모집 중3상
- NHO Revive Research Institute, Lincoln
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
피험자 모집 중3상
- Research Site, Lincoln
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
피험자 모집 중2상
- Nebraska Hematology-Oncology, Lincoln
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
피험자 모집 중2상
- USA14-0, Lincoln
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 121개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 57개
- Washington, DC연구 55개
Lincoln의 다른 연구
- 심부전연구 8개
- 폐암연구 7개
- 관상동맥질환연구 5개
- 조현병연구 4개
- 유방암연구 4개
- 대장직장암연구 4개
- 비만연구 4개
- 근위축성 측삭경화증연구 3개
- 암 (전체)연구 3개
- 다발성 골수종연구 3개
- 흑색종연구 3개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.